Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31316625 | 1.00 | MAPK1 (0.36) | MAPK1CHRM2CHRM1CHRM3EPHX1 | |
| SCHEMBL16286714 | 0.81 | MAPK1 (0.40) | MAPK1HRH3 | |
| SCHEMBL3780480 | 0.76 | MAPK1 (0.41) | MAPK1CHRM2CHRM1CHRM3THRB | |
| SCHEMBL1296115 | 0.74 | EPHX1 (0.41) | MAPK1CHRM2CHRM1CHRM3EPHX1 | |
| SCHEMBL25453169 | 0.74 | BTK (0.39) | MAPK1CHRM2CHRM1CHRM3EPHX1 | |
| SCHEMBL2502211 | 0.74 | BTK (0.39) | MAPK1CHRM2CHRM1CHRM3EPHX1 | |
| SCHEMBL30364247 | 0.74 | BTK (0.39) | MAPK1CHRM2CHRM1CHRM3EPHX1 | |
| SCHEMBL27551188 | 0.74 | EPHX1 (0.39) | MAPK1CHRM2CHRM1CHRM3EPHX1 | |
| SCHEMBL13624568 | 0.74 | NFKB1 (0.42) | EPHX1F2F10PRSS1 | |
| Hydrochloric Acid SCHEMBL27551210 | 0.73 | EPHX1 (0.38) | MAPK1CHRM2CHRM1CHRM3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118879800-A | Synthesis method of (R) -3-tert-butoxycarbonyl amino cyclohexanone | 苏州弗莱明生物技术有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MAPK1 494/4885CHRM2 3252/4885CHRM1 2869/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MAPK1 494/4885CHRM2 3252/4885CHRM1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.